Fleebs-Logo
Details werden geladen...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss | The Manila Times

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026.

Ähnliche Seiten

https://www.finanznachrichten.de/nachrichten-2026-06/68880008-ean-congress-hearing-aid-use-linked-to-23-lower-dementia-risk-in-people-with-both-epilepsy-and-hearing-loss-008.htm

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

https://www.finanznachrichten.de/nachrichten-2026-06/68880008-ean-congress-hearing-aid-use-linked-to-23-lower-dementia-risk-in-people-with-both-epilepsy-and-hearing-loss-008.htm
https://www.sciencealert.com/weight-loss-on-glp-1-drugs-linked-to-lower-risk-of-disease-study-finds

Weight Loss on GLP-1 Drugs Linked to Lower Risk of Disease, Study Finds : ScienceAlert

https://www.sciencealert.com/weight-loss-on-glp-1-drugs-linked-to-lower-risk-of-disease-study-finds
https://www.sciencedaily.com/releases/2026/06/260606075852.htm

Dementia risk linked to nitrate in drinking water, study finds | ScienceDaily

https://www.sciencedaily.com/releases/2026/06/260606075852.htm
https://www.manilatimes.net/2026/06/04/tmt-newswire/pr-newswire/era-congress-semaglutide-linked-to-better-quality-of-life-in-diabetes-and-kidney-disease-flow-trial-shows/2358351

ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows | The Manila Times

https://www.manilatimes.net/2026/06/04/tmt-newswire/pr-newswire/era-congress-semaglutide-linked-to-better-quality-of-life-in-diabetes-and-kidney-disease-flow-trial-shows/2358351
https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/johnson-johnson-presents-new-imaavy-nipocalimab-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalised-myasthenia-gravis/2373918

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis | The Manila T...

https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/johnson-johnson-presents-new-imaavy-nipocalimab-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalised-myasthenia-gravis/2373918
https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-neurologic-and-global-clinical-benefit-with-alxn1840-versus-standard-of-care-in-wilson-disease/2373970

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease | The Manila Times

https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-neurologic-and-global-clinical-benefit-with-alxn1840-versus-standard-of-care-in-wilson-disease/2373970